Perspective Therapeutics, Inc. (CATX) is a publicly traded Healthcare sector company. As of September 14, 2026, CATX trades at $2.85 with a market cap of $320.77M and a P/E ratio of -2.22. CATX moved +1.42% today. Year to date, CATX is +2.55%; over the trailing twelve months it is -16.86%. Its 52-week range spans $1.60 to $6.16. Analyst consensus is strong buy with an average price target of $12.60. Rallies surfaces CATX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for CATX shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $2.85 |
| Market Cap | $320.77M |
| P/E Ratio | -2.22 |
| EPS | $-1.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.16 |
| 52-Week Low | $1.60 |
| Volume | 87.44K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.45M |
| Net Income | $-81.38M |
| Gross Margin | 0.00% |
10 analysts cover CATX: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.60.